Unfortunately, it happens again and again that pharmaceutical companies do not archive their documentation but discard it, a violation of basic GMP requirements. Occasionally this is discovered during inspections. The number of unreported cases is certainly higher. Now Unexo Lifesciences, an Indian manufacturer, has been caught by the FDA.
Monday, December 2, 2024
Batch Production and Control Record discarded Unexo Lifesciences, India.
Torn batch production records were found in plastic bags on the rooftop. These included missing batch production records, which allegedly could not be found during an FDA inspection. Furthermore, duplicate, incomplete batch records with the same batch numbers and issuance dates as the batch records presented during the inspection were found among the torn records. Batch records were "retrospectively prepared" in order to present them to the inspectors.
Subscribe to:
Post Comments (Atom)
Gap Assessment Schedule M
To conduct a **gap assessment** between the **old Schedule M** and the **revised Schedule M** of the **Drugs and Cosmetics Rules, 1945**, we...
-
An FDA Warning Letter is a formal communication from the US Food and Drug Administration (FDA) notifying a company or individual of regulato...
-
The significant violations of CGMP regulations for finished products, which are mentioned in the Warning Letter, are listed as follows: ...
-
The company experienced seven out-of-limit (OOL) events for microbial content in a system used to generate a major component of drug product...
No comments:
Post a Comment